scholarly journals Regulated nuclear accumulation of a histone methyltransferase times the onset of heterochromatin formation inC. elegansembryos

2018 ◽  
Vol 4 (8) ◽  
pp. eaat6224 ◽  
Author(s):  
Beste Mutlu ◽  
Huei-Mei Chen ◽  
James J. Moresco ◽  
Barbara D. Orelo ◽  
Bing Yang ◽  
...  
2018 ◽  
Author(s):  
Beste Mutlu ◽  
Huei-Mei Chen ◽  
James J. Moresco ◽  
Barbara D. Orelo ◽  
Bing Yang ◽  
...  

ONE SENTENCE SUMMARYMET-2/SETDB1 and interactors (LIN-65/ATF7IP and ARLE-14/ARL14EP) initiate heterochromatin formation during embryogenesis.ABSTRACTHeterochromatin formation during early embryogenesis is timed precisely, but it has been elusive how this process is regulated. Here we report the discovery of a histone methyltransferase complex whose nuclear accumulation determines the onset of heterochromatin formation in C. elegans embryos. We find that the inception of heterochromatin generation coincides with the nuclear accumulation of the methyltransferase MET-2 (SETDB). The absence of MET-2 results in delayed and disturbed heterochromatin formation, whereas accelerated nuclear localization of the methyltransferase leads to precocious heterochromatin. We identify two factors that bind to and function with MET-2: LIN-65, which resembles ATF7IP, localizes MET-2 into nuclear hubs, and ARLE-14, orthologous to ARL14EP, promotes stable association of MET-2 with chromatin. These data reveal that nuclear accumulation of MET-2 in conjunction with LIN-65 and ARLE-14 regulates timing of heterochromatin domains during embryogenesis.


2021 ◽  
Vol 12 (12) ◽  
Author(s):  
Che-Wei Chang ◽  
Yu-Chia Shen ◽  
Shian-Jang Yan

AbstractHigh dietary sugar (HDS) is a modern dietary concern that involves excessive consumption of carbohydrates and added sugars, and increases the risk of metabolic disorders and associated cancers. However, epigenetic mechanisms by which HDS induces tumor progression remain unclear. Here, we investigate the role of heterochromatin, an important yet poorly understood part of the epigenome, in HDS-induced tumor progression of Drosophila Ras/Src and Ras/scrib tumor systems. We found that increased heterochromatin formation with overexpression of heterochromatin protein 1a (HP1a), specifically in tumor cells, not only decreases HDS-induced tumor growth/burden but also drastically improves survival of Drosophila with HDS and Ras/Src or Ras/scrib tumors. Moreover, HDS reduces heterochromatin levels in tumor cells. Mechanistically, we demonstrated that increased heterochromatin formation decreases wingless (wg) and Hippo (Hpo) signaling, thereby promoting apoptosis, via inhibition of Yorkie (Yki) nuclear accumulation and upregulation of apoptotic genes, and reduces DNA damage in tumor cells under HDS. Taken together, our work identified a novel epigenetic mechanism by which HP1a-mediated heterochromatin formation suppresses HDS-induced tumor progression likely by decreasing wingless and Hippo signaling, increasing apoptosis, and maintaining genome stability. Our model explains that the molecular, cellular, and organismal aspects of HDS-aggravated tumor progression are dependent on heterochromatin formation, and highlights heterochromatin as a therapeutic target for cancers associated with HDS-induced metabolic disorders.


2009 ◽  
Vol 21 (1) ◽  
pp. 102
Author(s):  
C. M. Johnson ◽  
R. A. Cabot

Successful cleavage development of mammalian embryos requires precise activation and repression of transcription. Covalent modifications to histone proteins, such as methylation and acetylation, play a key role in transcriptional regulation. In particular, dimethylation of the lysine 9 residue of histone protein H3 (H3K9) results in gene silencing and heterochromatin formation. Our lab has previously shown that transcripts encoding the five histone methyltransferases known to methylate H3K9 (Suv39h1, Suv39h2, ESET, G9a, and EHMT1) are present in different amounts during oocyte maturation and cleavage development. Specifically, Suv39h2 is in the greatest abundance in GV and metaphase II stage oocytes and is also present throughout cleavage development. The aim of this study was to determine the localization of Suv39h2 protein in the GV-stage oocyte and pronuclear, 2 cell, and 4 cell stage parthenogenetic porcine embryos. We hypothesized that Suv39h2 protein would localize to the nucleus based on its high transcript abundance throughout cleavage development. To test this hypothesis, we performed a microinjection experiment in which mRNA encoding a porcine Suv39h2-GFP fusion protein was injected into metaphase II porcine oocytes. Porcine oocytes were matured in a defined medium (TCM-199 supplemented with 0.1% PVA, 0.069 mg mL–1 cysteine, 10 ng mL–1 EGF, 0.5 IU mL–1 LH and FSH) for 42 to 44 h at 39°C in 5% CO2, then denuded of cumulus cells just before microinjection. Two separate treatment groups were microinjected intracytoplasmically with 1 μg μL–1 GFP or Suv39h2-GFP mRNA, respectively. Microinjection was performed using a FemtoJet microinjector (Eppendorf, Hamburg, Germany). The treatment groups and non-injected controls were electroactivated independently and cultured in PZM medium supplemented with 3 mg mL–1 BSA for 12 (pronuclear), 24 (2 cell), or 48 (4 cell) hours at 39°C in 5% CO2, depending on desired stage of development. Before visualization under UV light, embryos were stained with Hoechst 33342 for 15 minutes. Oocytes and embryos were analyzed for GFP expression at the GV, pronuclear, 2 and 4 cell stages of development using epifluorescence microscopy. Two to four biological replicates were performed for each stage of embryo development. We found that Suv39h2-GFP protein showed nuclear localization in most GV-stage oocytes (n = 11/14) and pronuclear (n = 17/17), 2-cell (n = 34/36), and 4-cell (n = 9/9) stage embryos. Chi square analysis revealed this pattern to be different from that observed in embryos injected with GFP mRNA, where GFP did not display nuclear localization at any stage of development (n = 12; P < 0.05). These results indicate that Suv39h2 is localized in the nucleus of oocytes and cleaved embryos, which suggests that this histone methyltransferase plays an important role in methylating H3K9.


Cell Reports ◽  
2016 ◽  
Vol 17 (3) ◽  
pp. 653-659 ◽  
Author(s):  
Richard T. Timms ◽  
Iva A. Tchasovnikarova ◽  
Robin Antrobus ◽  
Gordon Dougan ◽  
Paul J. Lehner

2020 ◽  
Author(s):  
Sofia Alexandra Milheiro ◽  
Joana Gonçalves ◽  
Ricardo Lopes ◽  
Margarida Madureira ◽  
Lis Lobo ◽  
...  

<p><a>A small library of “half-sandwich” cyclopentadienylruthenium(II) compounds of general formula [(</a>η<sup>5</sup>-C<sub>5</sub>R<sub>5</sub>)Ru(PPh<sub>3</sub>)(N-N)][PF<sub>6</sub>], a scaffold hitherto unfeatured in the toolbox of antiplasmodials, was screened for activity against the blood stage of CQ-sensitive 3D7-GFP, CQ-resistant Dd2 and artemisinin-resistant IPC5202 <i>Plasmodium falciparum</i> strains, and the liver stage of <i>P. berghei</i>. The best performing compounds displayed dual-stage activity, with single-digit nM IC<sub>50</sub> values against blood stage malaria parasites, nM activity against liver stage parasites, and residual cytotoxicity against mammalian cells (HepG2, Huh7). Parasitic absorption/distribution of 7-nitrobenzoxadiazole-appended fluorescent compounds <b>Ru4</b> and <b>Ru5</b> was investigated by confocal fluorescence microscopy, revealing parasite-selective absorption in infected erythrocytes and nuclear accumulation of both compounds. The lead compound <b>Ru2</b> impaired asexual parasite differentiation, exhibiting fast parasiticidal activity against both ring and trophozoite stages of a synchronized <i>P. falciparum</i> 3D7 strain. These results point to cyclopentadienylruthenium(II) complexes as a highly promising chemotype for the development of dual-stage antiplasmodials.</p>


Sign in / Sign up

Export Citation Format

Share Document